Decrease in major secondary bile acid, hyodeoxycholic acid, was the main alteration in hepatic bile acid compositions in a hypertensive nonalcoholic fatty liver disease model.
Animals
Bile Acids and Salts
/ chemistry
Choline Deficiency
/ metabolism
Chromatography, Liquid
Deoxycholic Acid
/ analysis
Disease Models, Animal
Hypertension
/ complications
Liver
/ metabolism
Male
Non-alcoholic Fatty Liver Disease
/ complications
Rats
Rats, Inbred SHR
Rats, Inbred WKY
Spectrometry, Mass, Electrospray Ionization
Tandem Mass Spectrometry
bile
hypertension
liver
nonalcoholic fatty liver disease
spontaneously hypertensive rat
Journal
Journal of hepato-biliary-pancreatic sciences
ISSN: 1868-6982
Titre abrégé: J Hepatobiliary Pancreat Sci
Pays: Japan
ID NLM: 101528587
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
pubmed:
29
9
2019
medline:
22
5
2020
entrez:
29
9
2019
Statut:
ppublish
Résumé
Previous findings on hepatic bile acid compositions in nonalcoholic fatty liver disease (NAFLD) have been inconsistent and complicated. The aim of this study was to investigate the effects of steatosis on hepatic bile acid composition in a hypertensive NAFLD model without obesity and diabetes mellitus and compare hepatic bile acid composition between hypertensive rats with and without steatosis. Two groups of hypertensive rats were studied: spontaneously hypertensive rats (SHR) fed with a normal diet (SHR-N) or a choline-deficient diet (SHR-CD). Two groups of normotensive rats were studied: Wistar Kyoto rats (WKY) fed a normal diet (WKY-N) or a choline-deficient diet (WKY-CD). Hepatic bile acid analysis was performed using liquid chromatography-electrospray ionization-tandem mass spectrometry. Regarding bile acid composition, the hyodeoxycholic acid (HDCA) species in the SHR-CD group showed the largest change in bile acid composition, significantly decreasing to 21.9% of that found in the SHR-N group. In the WKY-CD group, no reduction of HDCA species was observed. We demonstrated that the decrease in HDCA species was the main alteration in a hypertensive NAFLD model. It was suggested that the decrease in HDCA species in the SHR-CD group was caused by dysbiosis.
Sections du résumé
BACKGROUND
BACKGROUND
Previous findings on hepatic bile acid compositions in nonalcoholic fatty liver disease (NAFLD) have been inconsistent and complicated. The aim of this study was to investigate the effects of steatosis on hepatic bile acid composition in a hypertensive NAFLD model without obesity and diabetes mellitus and compare hepatic bile acid composition between hypertensive rats with and without steatosis.
METHODS
METHODS
Two groups of hypertensive rats were studied: spontaneously hypertensive rats (SHR) fed with a normal diet (SHR-N) or a choline-deficient diet (SHR-CD). Two groups of normotensive rats were studied: Wistar Kyoto rats (WKY) fed a normal diet (WKY-N) or a choline-deficient diet (WKY-CD). Hepatic bile acid analysis was performed using liquid chromatography-electrospray ionization-tandem mass spectrometry.
RESULTS
RESULTS
Regarding bile acid composition, the hyodeoxycholic acid (HDCA) species in the SHR-CD group showed the largest change in bile acid composition, significantly decreasing to 21.9% of that found in the SHR-N group. In the WKY-CD group, no reduction of HDCA species was observed.
CONCLUSIONS
CONCLUSIONS
We demonstrated that the decrease in HDCA species was the main alteration in a hypertensive NAFLD model. It was suggested that the decrease in HDCA species in the SHR-CD group was caused by dysbiosis.
Substances chimiques
Bile Acids and Salts
0
Deoxycholic Acid
005990WHZZ
hyodeoxycholic acid
7A33Y6EHYK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
557-567Informations de copyright
© 2019 Japanese Society of Hepato-Biliary-Pancreatic Surgery.
Références
Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
Vasuntab RL, Kesäniemi YA, Ylitalo AS, Ukkola OH. High ambulatory blood pressure values associated with non-alcoholic fatty liver in middle-aged adults. J Hypertens. 2012;30:2015-9.
Wang Y, Zeng Y, Lin C, Chen Z. Hypertension and non-alcoholic fatty liver disease proven by transient elastography. Hepatol Res. 2016;46:1304-10.
Ding X, Xu Y, Wang Y, Li X, Lu C, Su J, et al. Nonalcoholic fatty liver disease and associated metabolic risks of hypertension in type 2 diabetes: a cross-sectional community-based study. Int J Endocrinol. 2017;2017:5262560.
Fogari R, Maffioli P, Mugellini A, Zoppi A, Lazzari P, Derosa G. Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol. 2012;24:164-71.
Derosa G, Mugellini A, Pesce RM, D’Angelo A, Maffioli P. Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients. Eur J Pharmacol. 2015;766:31-6.
Ikuta T, Kanno K, Arihiro K, Matsuda S, Kishikawa N, Fujita K, et al. Spontaneously hypertensive rats develop pronounced hepatic steatosis induced by choline-deficient diet: evidence for hypertension as a potential enhancer in non-alcoholic steatohepatitis. Hepatol Res. 2012;42:310-20.
Yamamoto H, Kanno K, Ikuta T, Arihiro K, Sugiyama A, Kishikawa N, et al. Enhancing hepatic fibrosis in spontaneously hypertensive rats fed a choline-deficient diet: a follow-up report on long-term effects of oxidative stress in non-alcoholic fatty liver disease. J Hepatobiliary Pancreat Sci. 2016;23:260-9.
Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137-74.
Hofmann AF, Hagey LR. Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J Lipid Res. 2014;55:1553-95.
Juřica J, Dovrtělová G, Nosková K, Zendulka O. Bile acids, nuclear receptors and cytochrome P450. Physiol Res. 2016;65:S427-40.
Yang ZX, Shen W, Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol Int. 2010;4:741-8.
Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:e1.
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956-65.
Aranha MM, Cortez-Pinto H, Costa A, da Silva IB, Camilo ME, de Moura MC, et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2008;20:519-25.
Lake AD, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, et al. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol. 2013;268:132-40.
Jia X, Suzuki Y, Naito N, Yetti H, Kitamori K, Hayashi Y, et al. A possible role of chenodeoxycholic acid and glycine-conjugated bile acids in fibrotic steatohepatitis in a dietary rat model. Dig Dis Sci. 2014;59:1490-501.
Chávez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 2017;152:e3.
Anishchenko AM, Aliev OI, Sidekhmenova AV, Shamanaev AY, Plotnikov MB. Dynamics of blood pressure elevation and endothelial dysfunction in SHR rats during the development of arterial hypertension. Bull Exp Biol Med. 2015;159:591-3.
Folch J, Less M, Sloane-Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226:497-509.
Naritaka N, Suzuki M, Sato H, Takei H, Murai T, Kurosawa T, et al. Profile of bile acids in fetal gallbladder and meconium using liquid chromatography-tandem mass spectrometry. Clin Chim Acta. 2015;446:76-81.
Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut microbiota dysbiosis is linked to hypertension. Hypertension. 2015;65:1331-40.
Jose PA, Raj D. Gut microbiota in hypertension. Curr Opin Nephrol Hypertens. 2015;24:403-9.
Murakami M, Iwamoto J, Honda A, Tsuji T, Tamamushi M, Ueda H, et al. Detection of gut dysbiosis due to reduced clostridium subcluster XIVa using the fecal or serum bile acid profile. Inflamm Bowel Dis. 2018;24:1035-44.
Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA. 2001;98:3375-80.
Setchell KD, Rodrigues CM, Clerici C, Solinas A, Morelli A, Gartung C, et al. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology. 1997;112:226-35.